Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial
Vaccines(2024)
Key words
BNT162b2,COVID-19,SARS-CoV-2,vaccine,variant-adapted,booster,Omicron,XBB.1.5
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined